Drug Approval | May 29, 2024
Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The Product is expected to be the first generic approval on the market
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
